These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 35998502)

  • 1. Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.
    Liu Z; Han Y; Dang Q; Xu H; Zhang Y; Duo M; Lv J; Li H; Kong Y; Han X
    Int Immunopharmacol; 2022 Oct; 111():109173. PubMed ID: 35998502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
    van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
    Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
    Nabet BY; Esfahani MS; Moding EJ; Hamilton EG; Chabon JJ; Rizvi H; Steen CB; Chaudhuri AA; Liu CL; Hui AB; Almanza D; Stehr H; Gojenola L; Bonilla RF; Jin MC; Jeon YJ; Tseng D; Liu C; Merghoub T; Neal JW; Wakelee HA; Padda SK; Ramchandran KJ; Das M; Plodkowski AJ; Yoo C; Chen EL; Ko RB; Newman AM; Hellmann MD; Alizadeh AA; Diehn M
    Cell; 2020 Oct; 183(2):363-376.e13. PubMed ID: 33007267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.
    Jiang R; Cheng X; Li P; Meng E; Wu X; Wu H
    Sci Rep; 2024 Jun; 14(1):14027. PubMed ID: 38890392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
    JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
    Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
    Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
    Hellmann MD; Nabet BY; Rizvi H; Chaudhuri AA; Wells DK; Dunphy MPS; Chabon JJ; Liu CL; Hui AB; Arbour KC; Luo J; Preeshagul IR; Moding EJ; Almanza D; Bonilla RF; Sauter JL; Choi H; Tenet M; Abu-Akeel M; Plodkowski AJ; Perez Johnston R; Yoo CH; Ko RB; Stehr H; Gojenola L; Wakelee HA; Padda SK; Neal JW; Chaft JE; Kris MG; Rudin CM; Merghoub T; Li BT; Alizadeh AA; Diehn M
    Clin Cancer Res; 2020 Jun; 26(12):2849-2858. PubMed ID: 32046999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
    Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.
    Tang Q; Chen Y; Li X; Long S; Shi Y; Yu Y; Wu W; Han L; Wang S
    Front Immunol; 2022; 13():964442. PubMed ID: 36177034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
    Huang C; Liu S; Tong X; Fan H
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):171-183. PubMed ID: 29948020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
    Wang X; Wang F; Zhong M; Yarden Y; Fu L
    Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Circulating Tumor DNA for Cancer Immunotherapy.
    Snyder A; Morrissey MP; Hellmann MD
    Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
    Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W
    Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.
    Wang L; Yang Z; Guo F; Chen Y; Wei J; Dai X; Zhang X
    Front Immunol; 2023; 14():1227797. PubMed ID: 37465684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.